Skip to content

Systemic Thrombolysis Versus Catheter Directed Management for Acute Intermediate-high Pulmonary Embolism

In Hospital Clinical Outcomes and Short Term Follow up of Systemic Thrombolysis Versus Catheter Directed Management for the Treatment of Acute Intermediate-high Pulmonary Embolism

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06545864
Enrollment
50
Registered
2024-08-09
Start date
2024-10-01
Completion date
2030-03-01
Last updated
2024-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Pulmonary Embolism

Keywords

intermediate-high, acute pulmonary embolism, systemic thrombolysis, catheter- directed management

Brief summary

To compare in hospital clinical outcomes and one month follow up of systemic thrombolysis versus catheter directed management for the treatment of acute intermediate- high risk pulmonary embolism (using streptokinase or tissue plasminogen activator (TPA) and catheter-based intervention group using Penumbra System).

Interventions

DRUGStreptokinase Injection

250000 IU as a loading dose over 30 min. Followed by 100000 IU/hour over 12:24hours or accelerated regimen 1.5 million IU over 2 hours

which comprised of several devices: * RED Reperfusion Catheters * Penumbra JET Reperfusion Catheters * ACE Reperfusion Catheters * MAX Reperfusion Catheters * 3D Revascularization Device * Penumbra ENGINE Aspiration Source * Penumbra ENGINE Canister * Aspiration Tubing

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients diagnosed with acute intermediate-high pulmonary embolism

Exclusion criteria

* Patients less than 18 years of age. * Low risk, intermediate low risk, acute pulmonary embolism * patients with RV masses will be excluded. * Patient refusal of treatment strategy.

Design outcomes

Primary

MeasureTime frameDescription
Duration of hospital stay.during hospital stay (about 1 week)
Change of RV signs of PE by Transthoracic echocardiographyduring hospital stay (about 1 week) and one month after discharge
Need for mechanical ventilation.during hospital stay (about 1 week)
Need for surgical intervention.during hospital stay (about 1 week)surgical embolectomy
Change in blood pressureduring hospital stay (about 1 week) and one month after discharge
Change in heart rateduring hospital stay (about 1 week) and one month after discharge
Change in respiratory rateduring hospital stay (about 1 week) and one month after discharge
Change of O2 saturation.during hospital stay (about 1 week)

Secondary

MeasureTime frameDescription
incidence of pericardial effusionduring hospital stay (about 1 week) and one month after dischargedue to: infection cardiac perforation during catheter directed interventions
incidence of Major bleedingduring hospital stay (about 1 week) and one month after dischargethat requires blood transfusions or urgent intervention
incidence of Perforation of pulmonary arteryduring hospital stay (about 1 week)may occur during catheter directed interventions

Countries

Egypt

Contacts

Primary Contactmariam J william
mariamjoseph1997@gmail.com01009083119

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026